SLC5A1, solute carrier family 5 member 1, 6523

N. diseases: 94; N. variants: 12
Disease: Diabetes ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0011847
Disease: Diabetes
Diabetes 		0.100 Biomarker disease BEFREE SGLT1 inhibition boon or bane for diabetes-associated cardiomyopathy. 31698522 2020
CUI: C0011847
Disease: Diabetes
Diabetes 		0.100 Biomarker disease BEFREE Glucose reabsorption in the proximal tubule (via Sglt1 and Sglt2) has emerged as an important contributor to the development of diabetes. 30484350 2019
CUI: C0011847
Disease: Diabetes
Diabetes 		0.100 Biomarker disease BEFREE Dual inhibition of SGLT1/2 with licogliflozin in the gut and kidneys is an attractive strategy for treating obesity and diabetes. 30724002 2019
CUI: C0011847
Disease: Diabetes
Diabetes 		0.100 Biomarker disease BEFREE Clinical trials evaluating inhibitors of AAK1 (neuropathic pain) and SGLT1 (diabetes) are underway. 31064765 2019
CUI: C0011847
Disease: Diabetes
Diabetes 		0.100 AlteredExpression disease BEFREE Thus, we aim to examine whether FGF-21 regulates expression of intestinal SGLT1 in diabetes. 30551357 2019
CUI: C0011847
Disease: Diabetes
Diabetes 		0.100 Biomarker disease BEFREE Using a Mendelian randomization approach in the index cohort, the estimated 25-year effect of a reduction of 20 mg/dl in 2-h glucose via SGLT1 inhibition would be reduced prevalent obesity (OR: 0.43; 95% CI: 0.23 to 0.63), incident diabetes (hazard ratio [HR]: 0.58; 95% CI: 0.35 to 0.81), heart failure (HR: 0.53; 95% CI: 0.24 to 0.83), and death (HR: 0.66; 95% CI: 0.42 to 0.90). 30286918 2018
CUI: C0011847
Disease: Diabetes
Diabetes 		0.100 Biomarker disease BEFREE Sotagliflozin is the first dual SGLT1/SGLT2 inhibitor developed for use in diabetes. 29212386 2018
CUI: C0011847
Disease: Diabetes
Diabetes 		0.100 Biomarker disease BEFREE As a consequence, the inhibition of SGLT1 transporters may represent an interesting therapeutic option in patients with diabetes. 30240793 2018
CUI: C0011847
Disease: Diabetes
Diabetes 		0.100 Biomarker disease BEFREE A recently investigated strategy to employ orally applied SGLT1 (SLC5A1) inhibitors for treatment of diabetes is discussed. 27773781 2017
CUI: C0011847
Disease: Diabetes
Diabetes 		0.100 Biomarker disease BEFREE In whole renal tissue, expressions of SGLT2/GLUT2 and SGLT1/GLUT1 are coupled and slightly lower in typical people with T2DM as compared with well-matched people without diabetes. 28419670 2017